We are live on ! Find out more

Alpha Teknova

TKNO

Market cap $397M

7.39 USD

+0.59

8.68%

At close Updated Oct 20, 4:00 PM EDT

Pre-market

After hours

5.09

-2.30

31.12%

1 day

8.68%

5 days

-9.33%

1 month

-11.39%

3 months

39.43%

6 months

153.95%

Year to date

89.49%

1 year

28.52%

5 years

-69.03%

10 years

-70.44%

About: Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

Employees: 158

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 43.8%

Neutral 56.3%

Negative 0%

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the pricing of its underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $40 million. Teknova has also granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of its common stock. All of the shares of common stock in the offering are to be sold by Teknova. The offering is expected to close on or about October 22, 2026, subject to the satisfaction of customary closing conditions.

Teknova Announces Pricing of $40 Million Public Offering of Common Stock

Teknova Announces Proposed Public Offering of Common Stock

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has commenced an underwritten public offering of its common stock. Teknova also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock offered in the offering. All of the shares of common stock to be sold in the proposed offering are to be sold by Teknova. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Teknova Announces Proposed Public Offering of Common Stock

Teknova Announces Preliminary Third Quarter Financial Results

HOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced in conjunction with its filing of a preliminary prospectus supplement, preliminary unaudited financial results for the three months ended September 30, 2026.

Teknova Announces Preliminary Third Quarter Financial Results

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Teknova and Pluristyx announce a Type II FDA Drug Master File for the PluriFreeze™ cryopreservation system, now available to developers for cross-reference

Teknova and Pluristyx Announce FDA Drug Master File for the PluriFreeze™ Cryopreservation System

Zacks Investment Research

All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy

Alpha Teknova (TKNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Alpha Teknova (TKNO) Rating Upgrade to Buy

Zacks Investment Research

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Alpha Teknova (TKNO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alpha Teknova (TKNO) Moves 7.1% Higher: Will This Strength Last?

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Teknova's Fill-Tek™ Dispensing System fills single-use bag orders across multiple sizes and quantities as a single lot, with no added turnaround time.

Teknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag Filling

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Alpha Teknova NASDAQ: TKNO Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Zacks Investment Research

Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?

Does Alpha Teknova (TKNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Alpha Teknova (TKNO) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade

The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade

See News Rankings

Price charts implemented using Lightweight Charts™